-

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January:

  • Goldman Sachs Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 5, 2023 at 9:45 am (EST)
  • 41st Annual J. P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 am (PST)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. 

Contacts

Incyte
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Versions
English

Contacts

Incyte
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

More News From Incyte

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis...

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates...
Back to Newsroom